Summary
Eli Lilly & Company (LLY) announced on October 6, 2008, its entry into a definitive Agreement and Plan of Merger with ImClone Systems Incorporated. This agreement outlines the terms for Lilly, through its wholly-owned subsidiary Alaska Acquisition Corporation, to commence a tender offer for all outstanding ImClone common stock. The proposed transaction involves a cash tender offer at a price of $70 per share. This strategic move signals Lilly's intent to acquire ImClone, a development that could significantly impact Lilly's product portfolio and future growth trajectory, particularly in areas where ImClone has a presence. Investors should monitor the tender offer process and any subsequent developments regarding this acquisition.
Key Highlights
- 1Eli Lilly & Company entered into an Agreement and Plan of Merger with ImClone Systems Incorporated.
- 2Lilly will acquire ImClone through a tender offer initiated by its wholly-owned subsidiary, Alaska Acquisition Corporation.
- 3The tender offer price is set at $70 per share in cash for all outstanding ImClone common stock.
- 4This filing is an 8-K report, indicating a material event for the company.
- 5The announcement was made via a press release dated October 6, 2008, attached as Exhibit 99.1.